Showing 10 of 10 recruiting trials for “Angelman syndrome due to a point mutation”
RecruitingNCT07417137 ↗
A Natural History Study of Angelman Syndrome
👨⚕️ Christopher J Keary, MD, Massachusetts General Hospital📍 1 site📅 Started Mar 2026View details ↗
A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
RecruitingNCT06737718 ↗
Use of Eye Tracking to Study Social Perception Abnormalities in Children With Angelman Syndrome
👨⚕️ Nathalie MD, PhD Boddaert, Assistance Publique - Hôpitaux de Paris📍 1 site📅 Started Feb 2025View details ↗
Long-term Extension of GTX-102 in Angelman Syndrome
RecruitingNCT06115109 ↗
Angelman Natural History Study - FAST Spain
👨⚕️ BELEN RUIZ ANTORAN, MD, Ph, Clinical Pharmacology Deparment, Hospital Universitario Puerta de Hierro Majadahonda📍 2 sites📅 Started Dec 2023View details ↗
RecruitingNCT06337383 ↗
Study of the Prevalence of Autistic Traits in Angelman Syndrome
👨⚕️ Martina Baggio, Scientific Institute IRCCS E. Medea, Epilepsy Unit, Conegliano 31015, Italy📍 1 site📅 Started Mar 2022View details ↗
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
RecruitingNCT06229769 ↗
Natural History Study for Patients With Angelman Syndrome
RecruitingNCT05293184 ↗
The Global Angelman Syndrome Registry
👨⚕️ Helen (Honey) Heussler, MBBS, FRACP DM, The University of Queensland📍 1 site📅 Started Sep 2016View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →